MSF urges Indian Patent Office to reject Gilead Sovaldi patent

Médecins Sans Frontières (MSF) has urged the Indian Patent Office (IPO) to reject a Gilead Sciences patent application covering Sovaldi (sofosbuvir).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Asia-Pacific

Gilead gets Sovaldi patent approval in India despite opposition

10 May 2016 Gilead has been granted a patent for its hepatitis C drug Sovaldi in India, despite concerns over the cost of the drug.

Asia

Indian drug makers end generic bids

18 April 2016 Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

MSF urges Indian Patent Office to reject Gilead Sovaldi patent

More on this story

Editor's picks

Editor's picks

More features